Guidance to bone morbidity in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation
Kuhlen, Michaela; Kunstreich, Marina; Niinimäki, Riitta; Dunstheimer, Desiree; Lawitschka, Anita; Bardi, Edit; Willasch, André; Bader, Peter; Högler, Wolfgang; Peters, Christina; Balduzzi, Adriana (2019-10-13)
Michaela Kuhlen, Marina Kunstreich, Riitta Niinimäki, Desiree Dunstheimer, Anita Lawitschka, Edit Bardi, André Willasch, Peter Bader, Wolfgang Högler, Christina Peters, Adriana Balduzzi, Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, Volume 26, Issue 2, 2020, Pages e27-e37, ISSN 1083-8791, https://doi.org/10.1016/j.bbmt.2019.10.007
© 2019. American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://urn.fi/URN:NBN:fi-fe2020051127231
Tiivistelmä
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is widely performed in children and adolescents with hematologic diseases, including very high-risk leukemia. With increasing success and survival rates, the long-term sequelae of HSCT have become important. Here, we provide guidance to the prevention and treatment of the most common bone morbidities—osteoporosis and osteonecrosis—emerging in the context of HSCT in children and adolescents. We give an overview on definitions, symptoms, and diagnostics and propose an algorithm for clinical practice based on discussions within the International Berlin Frankfurt Münster (BFM) Stem Cell Transplantation Committee and the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, our expert knowledge, and a literature review.
Kokoelmat
- Avoin saatavuus [36660]
